SD Biosensor Posts Q1 2026 Net Profit Turnaround and Announces Treasury Share Cancellation Plan

Q1 2026 consolidated revenue: KRW 193.5bn, operating loss KRW 11.6bn (improving), net profit KRW 22.3bn (turnaround to black)
Treasury share cancellation: 1 million shares cancelled on Mar 17, 2026; additional 1 million shares/year planned for 2027-2028
Dividend policy: target at least 20% of separate operating income
Key risk: ongoing patent infringement lawsuit with (주)Rapigen (claim amount KRW 100.2bn)
Financial health: debt ratio 24.1%, cash & equivalents KRW 184.2bn
R&D expenditure: KRW 22.3bn (11.5% of revenue)